Mesalamine Controlled-Release Capsules and Mogamulizumab-kpkc Intravenous
Determining the interaction of Mesalamine Controlled-Release Capsules and Mogamulizumab-kpkc Intravenous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: mesalamine
Brand name: Apriso, Asacol HD, Delzicol, Lialda, Pentasa, Canasa, Canasa Pac, Rowasa, SfRowasa
Synonyms: Mesalamine
Generic Name: mogamulizumab
Brand name: Poteligeo
Synonyms: Mogamulizumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Mesalamine Controlled-Release Capsules-Molindone
- Mesalamine Controlled-Release Capsules-Mometasone (Oral Inhalation)
- Mesalamine Controlled-Release Capsules-Mometasone and Formoterol
- Mesalamine Controlled-Release Capsules-Mometasone and formoterol Inhalation
- Mesalamine Controlled-Release Capsules-Mometasone Cream
- Mesalamine Controlled-Release Capsules-Mometasone Furoate
- Mogamulizumab-kpkc Intravenous-Mesalamine Delayed Release Tablets
- Mogamulizumab-kpkc Intravenous-Mesalamine Long-Acting Capsules (Apriso)
- Mogamulizumab-kpkc Intravenous-Mesalamine Long-Acting Capsules (Delzicol)
- Mogamulizumab-kpkc Intravenous-Mesalamine Long-Acting Capsules (Pentasa)
- Mogamulizumab-kpkc Intravenous-Mesalamine rectal
- Mogamulizumab-kpkc Intravenous-Mesalamine Rectal Enema